Calpain system protein expression in basal-like and triple-negative invasive breast cancer

Annals of Oncology

Volumn 23, Issue 9, 2012, Pages 2289-2296

  Storr, S J ^a   Lee, K W ^a   Woolston, C M ^a   Safuan, S ^a   Green, A R ^a   Macmillan, R D ^b   Benhasouna, A ^a   Parr, T ^a   Ellis, I O ^a   Martin, S G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Basal; Breast cancer; Calpain; Calpastatin; Triple negative

Indexed keywords

CALPAIN; CALPAIN 1; CALPAIN 2; CALPASTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE; PROTEINASE;

ADULT; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CELL FUNCTION; CELL SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SCORING SYSTEM; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER;

EID: 84865553987     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds176     Document Type: Article

References (28)

1. Carey L, Winer E, Viale G et al. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 2010; 7: 683-692.
2. Murad TM. A proposed histochemical and electron microscopic classification of human breast cancer according to cell of origin. Cancer 1971; 27: 288-299.
3. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
4. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423.
5. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
6. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008; 26: 2568-2581.
7. Zhang H, Rakha EA, Ball GR et al. The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. Breast Cancer Res Treat 2010; 121: 41-51.
8. Ray PS, Wang J, Qu Y et al. FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res 2010; 70: 3870-3876.
9. Biganzoli E, Coradini D, Ambrogi F et al. p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features. Jpn J Clin Oncol 2011; 41: 172-179.
10. Alexander BM, Sprott K, Farrow DA et al. DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer. Clin Cancer Res 2010; 16: 5796-5804.
11. Mehta R, Jain RK, Sneige N et al. Expression of high-molecular-weight cytokeratin (34betaE12) is an independent predictor of disease-free survival in patients with triple-negative tumours of the breast. J Clin Pathol 2010; 63: 744-747.
12. Goll DE, Thompson VF, Li H et al. The calpain system. Physiol Rev 2003; 83: 731-801.
13. Storr SJ, Carragher NO, Frame MC et al. The calpain system and cancer. Nat Rev Cancer 2011; 11: 364-374.
14. Storr SJ, Woolston CM, Barros FF et al. Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy. Int J Cancer 2010; 129: 1773-1780.
15. Storr SJ, Mohammed RA, Woolston CM et al. Calpastatin is associated with lymphovascular invasion in breast cancer. Breast 2011; 20: 413-418.
16. Libertini SJ, Robinson BS, Dhillon NK et al. Cyclin E both regulates and is regulated by calpain 2, a protease associated with metastatic breast cancer phenotype. Cancer Res 2005; 65: 10700-10708.
17. Agarwal R, Gonzalez-Angulo AM, Myhre S et al. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 2009; 15: 3654-3662.
18. Heiser LM, Sadanandam A, Kuo WL et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci USA 2012; 109: 2724-2729.
19. Abdel-Fatah TM, Powe DG, Agboola J et al. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. J Pathol 2010; 220: 419-434.
20. Rakha EA, El-Rehim DA, Paish C et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 2006; 42: 3149-3156.
21. McShane LM, Altman DG, Sauerbrei W et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol 2005; 2: 416-422.
22. Abd El-Rehim DM, Ball G, Pinder SE et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005; 116: 340-350.
23. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004; 10: 7252-7259.
24. Cheang MC, Voduc D, Bajdik C et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368-1376.
25. Glading A, Uberall F, Keyse SM et al. Membrane proximal ERK signaling is required for M-calpain activation downstream of epidermal growth factor receptor signaling. J Biol Chem 2001; 276: 23341-23348.
26. Xu L, Deng X. Protein kinase Ciota promotes nicotine-induced migration and invasion of cancer cells via phosphorylation of micro- and m-calpains. J Biol Chem 2006; 281: 4457-4466.
27. Neumar RW, Meng FH, Mills AM et al. Calpain activity in the rat brain after transient forebrain ischemia. Exp Neurol 2001; 170: 27-35.
28. Goncalves I, Nitulescu M, Saido TC et al. Activation of calpain-1 in human carotid artery atherosclerotic lesions. BMC Cardiovasc Disord 2009; 9: 26.